Condition: Advanced or Metastatic Solid Tumors · Breast Cancer · Ovarian Cancer · Sponsor: 858 Therapeutics, Inc.
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.
This description comes directly from the study's public registry record.
858 Therapeutics, Inc. · (858) 987-8380 · dmccormick@8five8tx.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| Yale University, Yale Cancer Center | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Stefanie Spielman Comprehensive Breast Center | Columbus, Ohio, United States | Recruiting |
| Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center | Philadelphia, Pennsylvania, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| START Center for Cancer Care - Mountain Region | Salt Lake City, Utah, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06395519